Xilio Therapeutics (XLO) Enterprise Value (2021 - 2026)

Xilio Therapeutics has disclosed Enterprise Value across 6 years of filings, most recently posting $49.9 million for Q2 2026.

• In Q2 2026, Enterprise Value rose 189.07% year-over-year to $49.9 million; the TTM figure through Jun 2026 stood at $49.9 million (up 189.07% YoY), while the FY2025 annual figure was -$62.6 million, down 440.04% from the prior year.
• Enterprise Value came in at $49.9 million for Q2 2026 at Xilio Therapeutics, up from -$12.9 million in the prior quarter.
• In the past five years, Enterprise Value ranged from a high of $49.9 million in Q2 2026 to a low of -$79.4 million in Q2 2022.
• Average Enterprise Value over 5 years is -$19.7 million, with a median of -$12.2 million recorded in 2024.
• The largest YoY upside for Enterprise Value was 256.9% in 2025 against a maximum downside of 811.69% in 2025.
• Over 5 years, Enterprise Value stood at -$46.6 million in 2022, then soared by 36.67% to -$29.5 million in 2023, then jumped by 60.73% to -$11.6 million in 2024, then sank by 440.04% to -$62.6 million in 2025, then jumped by 179.63% to $49.9 million in 2026.
• Per Business Quant data, the three most recent Enterprise Value figures were $49.9 million in Q2 2026, -$12.9 million in Q1 2026, and -$62.6 million in Q4 2025.